In fact, while Nrf2 initially acts as a cancer-preventive factor, protecting cells from carcinogens and oxidative stress, the persistent activation of Nrf2 activates its oncogene properties and reduces radiotherapy- and chemotherapy-induced cytotoxicity, enhancing drug resistance in cancer cells [46]. The gene discussed is NFE2L2; the disease is cancer.